The proposition to restrict or administratively ban direct-to-consumer (DTC) pharmaceutical advertisements, as reportedly considered by Health and Human Services Secretary Robert F. Kennedy, Jr., raises both constitutional and procedural concerns. There appears to be momentum behind this initiative, with Kennedy’s reported support for the No Handouts for Drug Advertisements Act, alongside legislative movements in Congress such as the End Prescription Drug Ads Now Act led by Senators Bernie Sanders and Angus King.
Several assumptions underpinning these proposals could be flawed. One is the belief that DTC ads significantly drive America’s drug consumption and costs, although the Food and Drug Administration (FDA) mandates the truthfulness of these advertisements. Various factors, including high obesity rates in the U.S., arguably play a more substantial role in medication demand, as suggested when considering countries like Japan, which has a much lower prevalence of obesity but also allows DTC advertisements (source).
Another assumption is that eliminating DTC ads would lead to lower drug prices or increased R&D spending. However, with DTC advertising accounting for just a portion of pharmaceutical companies’ massive revenues (1.63% according to industry figures), it seems unlikely the absence of these ads would materially impact drug pricing or research. The Congressional Budget Office has projected a mere 0.1% to 1% possible reduction in drug prices from eliminating DTC ads (source).
Furthermore, the notion that pharmaceutical ads dominate and influence broadcasting networks is contradicted by their financial structures, where DTC ads contribute only minimally to overall revenue. Network executives maintain that other income sources like licensing fees and subscriptions dwarf ad revenue. This undermines the argument that pharmaceutical companies exert undue influence over broadcasters (source).
Critically, any ban or crippling restriction on DTC advertising is likely to be met with substantial constitutional challenges. The US Supreme Court has long upheld protections for commercial speech under the First Amendment, as in the landmark Virginia State Board of Pharmacy v. Virginia Citizens Consumer Council case. Subsequently, rulings in Central Hudson Gas & Elec. v. Public Svc. Comm’n and Sorrell v. IMS Health further emphasized that any limits on such speech must be precisely targeted and built on demonstrable governmental interest.
Ultimately, the hurdles faced by legislative or administrative attempts to curb DTC advertisements suggest these efforts, while perhaps well-intentioned in addressing drug costs, must navigate carefully through the legal and constitutional frameworks recognized by courts. Achieving the goal of reducing medication and healthcare costs requires strategies consistent with both constitutional principles and the commercial realities of the pharmaceutical industry.
For more detailed analysis by legal scholar John Shu, visit the full discussion here.